Mike Westby Selected Research

Indicators and Reagents (Reagents)

9/2011

Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mike Westby Research Topics

Disease

11	Infections 07/2013 - 01/2005
3	HIV Infections (HIV Infection) 04/2010 - 01/2005
1	Melanoma (Melanoma, Malignant) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Bacterial Infections (Bacterial Infection) 06/2015
1	Lymphopenia (Lymphocytopenia) 10/2012
1	Virus Diseases (Viral Diseases) 09/2011
1	Disease Progression 01/2009
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2005

Drug/Important Bio-Agent (IBA)

7	Maraviroc FDA Link 03/2010 - 01/2005
5	Pharmaceutical PreparationsIBA 01/2019 - 01/2009
3	Antiviral Agents (Antivirals)IBA 04/2010 - 01/2005
2	Chemokine ReceptorsIBA 01/2009 - 01/2005
1	Complement System Proteins (Complement)IBA 01/2019
1	VaccinesIBA 01/2019
1	AntibodiesIBA 01/2019
1	AntigensIBA 01/2019
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2019
1	Complement C2 (Complement Component 2)IBA 01/2019
1	GalactosyltransferasesIBA 01/2019
1	GlycolipidsIBA 01/2019
1	Heterophile AntigensIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2015
1	Biomarkers (Surrogate Marker)IBA 10/2012
1	Toll-Like Receptor 7IBA 10/2012
1	CytokinesIBA 10/2012
1	filibuvirIBA 03/2012
1	RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)IBA 03/2012
1	Indicators and Reagents (Reagents)IBA 09/2011
1	InterferonsIBA 09/2011
1	RNA (Ribonucleic Acid)IBA 09/2010
1	Zidovudine (Retrovir)FDA LinkGeneric 03/2010
1	efavirenz (Sustiva)FDA Link 03/2010
1	Lamivudine (Epivir)FDA Link 03/2010
1	Enfuvirtide (Fuzeon)FDA Link 01/2009
1	aplavirocIBA 01/2005
1	vicrivirocIBA 01/2005

Therapy/Procedure

3	Therapeutics 01/2019 - 10/2012
1	Immunotherapy 01/2019